Peer-influenced content. Sources you trust. No registration required. This is HCN.
Cancer Therapy Advisor
Recent findings from the ASCO Gastrointestinal Cancers Symposium 2024 underscore the potential of innovative therapeutic combinations in enhancing outcomes for hepatocellular carcinoma patients, particularly those with unresectable or high-risk disease.
Oncology, Medical February 12th 2024
Dana-Farber Cancer Institute
In the landmark KEYNOTE-564 trial, pembrolizumab has emerged as a pivotal advancement in kidney cancer treatment, offering hope by significantly prolonging survival in patients with high-risk ccRCC post-nephrectomy.
The New England Journal of Medicine
The POLARIX trial reveals polatuzumab vedotin with R-CHP as a promising first-line therapy for DLBCL, showing a 27% reduction in the risk of progression, relapse, or death and a progression-free survival rate of 76.7% at 2 years.
Hematology/Oncology February 12th 2024
In this Phase 3 trial, resmetirom demonstrated a notable capacity to induce NASH resolution and improve liver fibrosis, offering hope for a therapeutic breakthrough in a field with limited treatment options. This study emphasizes the importance of advancing research in liver-directed therapies for NASH.
Gastroenterology February 12th 2024
Psychiatrist.com
In a phase 3 study, iloperidone demonstrated a significant improvement in treating bipolar mania, marked by a reduction in the Young Mania Rating Scale (YMRS) scores.
Psychiatry February 6th 2024
NEJM Evidence
In a recent phase II trial, patients with untreated metastatic pancreatic ductal adenocarcinoma receiving sequential nab-P/Gem-mFOLFOX experienced a median overall survival of 13.2 months, compared to 9.7 months in those receiving standard nab-P/Gem treatment, indicating a notable improvement in survival outcomes.
Oncology, Medical February 5th 2024